Brain Tumors

Latest Articles

Temozolomide Bests Nivolumab in Glioblastoma With Unmethylated MGMT Promoter

Overall and progression-free survival were superior with temozolomide.

MRI Radiomics Prediction Model for Patients With Glioma Shows Stability

Researchers sought to develop and validate an MRI radiomics prediction model through a machine learning-based method to predict the survival of patients with glioma.

Dabrafenib Plus Trametinib Effective for Gliomas With BRAF V600E Mutations

Researchers sought to evaluate the activity and safety of dabrafenib plus trametinib in adult patients with recurrent or progressive BRAF V600E -mutation–positive high-grade and low-grade glioma.

Cabozantinib Shows Promise for Renal Cell Carcinoma With Brain Metastases

The researchers sought to assess the safety and efficacy of cabozantinib to treat brain metastases in patients with metastatic renal cell carcinoma.

2008 to 2017 Saw Decrease in Malignant Brain Tumor Incidence

From 2008 to 2017, the incidence of malignant brain tumors decreased for all ages combined, but increased among children and adolescents.

Predictive Models for Clinical Characteristics Linked to Pediatric Neurofibromatosis Type 1

Researchers applied a machine learning strategy in a longitudinal analysis of clinical features linked to neurofibromatosis type 1 in pediatric patients.

Very Elderly Can Benefit From Brain Tumor Surgery

Surgical treatment of intracranial meningioma (IM) should be considered even in patients over the age of 80 years.

Patients in Bind as Brain Cancer Drug Price Rises to $1,000 Per Pill

The maker of the expensive brain cancer drug Gleostine has removed it from the Medicare drug rebate program.

Combination Immunotherapy Effective for Patients With Melanoma and Asymptomatic Brain Metastases

The combination of nivolumab with ipilimumab is an effective treatment option for patients with advanced melanoma with asymptomatic brain metastases

Occult Brain Metastasis Detected in Patients With Advanced Renal Cancer

Occult brain metastasis is identified in about 4 percent of patients with metastatic renal cell carcinoma (mRCC).